A Phase 1 interventional study of BI 1387446 50 μg and BI 754091 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer. In this study, BI 1387446 is given to humans for the first time.
The purpose of this study is to find out the highest dose of BI 1387446 alone and in combination with BI 754091 the participants can tolerate. BI 1387446 is injected directly into the tumour.
Participants get BI 1387446 injections every week at the beginning and then every 3 weeks.
Some participants get BI 754091 in addition to BI 1387446. BI 754091 is given as an infusion into a vein every 3 weeks.
As long as they benefit from treatment and can tolerate it, participants can stay in the study for up to 2 years and 8 months. During this time, they visit the study site regularly. At these visit, doctors record any unwanted effects. The doctors also regularly check participants' health.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 42 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered 50 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. The injection volume depended on tumor diameter.
Drug: BI 1387446 50 μg
Participants were administered 100 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. The injection volume depended on tumor diameter.
Drug: BI 1387446 100 μg
Participants were administered 200 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. The injection volume depended on tumor diameter.
Drug: BI 1387446 200 μg
Participants were administered 400 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. The injection volume depended on tumor diameter.
Drug: BI 1387446 400 μg
Participants were administered 50 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. BI 754091 (ezabenlimab) was administered intravenously at the recommended phase II dose of 240 mg once every 3 weeks. The maximum duration of ezabenlimab treatment was 34 cycles. BI 1387446 injections were preferably performed after completing the ezabenlimab infusion.
Drug: BI 754091
Participants were administered 100 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. BI 754091 (ezabenlimab) was administered intravenously at the recommended phase II dose of 240 mg once every 3 weeks. The maximum duration of ezabenlimab treatment was 34 cycles. BI 1387446 injections were preferably performed after completing the ezabenlimab infusion.
Drug: BI 754091
Participants were administered 200 μg of BI 1387446 intratumorally under visual inspection for visible skin tumors or under imaging guidance. BI 754091 (ezabenlimab) was administered intravenously at the recommended phase II dose of 240 mg once every 3 weeks. The maximum duration of ezabenlimab treatment was 34 cycles. BI 1387446 injections were preferably performed after completing the ezabenlimab infusion.
Drug: BI 754091
Participants received 50 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
Participants received BI 754091 (ezabenlimab) intravenously at a dose of 240 mg once every 21-day cycle.
Also known as: Ezabenlimab
Participants received 100 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
Participants received 200 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
Participants received 400 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
Maximum Tolerated Dose (MTD) Based on Number of Dose-limiting Toxicities (DLTs)
The MTD in each arm is defined as the highest dose that is expected to cause less than 25% risk of the true DLT rate being above or equal to 33% during the MTD evaluation period. Estimation of the MTD will be based upon the estimation of the posterior probability of the incidence of DLT in toxicity categories during the MTD evaluation period for all evaluable participants. The MTD evaluation period is defined as the time from the first administration of any trial medication to the start of the second treatment cycle. Specifically, this is the time from the first dose to either the second administration of ezabenlimab or the fourth administration of BI 1387446, whichever occurs first. If the second dose of ezabenlimab or the fourth dose of BI 1387446 is not given, the evaluation period ends 90 days after the last administration.
Time frame: From first administration of BI 1387446 until to end of treatment cycle 1 (up to 3 weeks).
Number of Patients With DLT in the MTD Evaluation Period
The MTD evaluation period is defined as the time from the first administration of any trial medication to the start of the second treatment cycle. Specifically, this is the time from the first dose to either the second administration of ezabenlimab or the fourth administration of BI 1387446, whichever occurs first. If the second dose of ezabenlimab or the fourth dose of BI 1387446 is not given, the evaluation period ends 90 days after the last administration.
Time frame: From first administration of BI 1387446 until to end of treatment cycle 1 (up to 3 weeks).
Objective Response Based on Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)
Objective response, as defined by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1), in accordance with Clinical Trial Protocol (CTP) Version 1 and 2, will be presented in terms of the objective response rate (ORR). The ORR is the proportion of patients whose best overall response is a confirmed complete response (CR) or partial response (PR). This determination is based on the investigator's assessment according to RECIST 1.1 criteria, from the date of the first treatment administration until the earliest occurrence of any of the following events: disease progression, death, the last evaluable tumor assessment before the initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients are shown in both Arm A (reflecting their initial treatment) and Arm B (reflecting their first treatment post-crossover). Their best overall response is counted, regardless of whether it occurred before or after the crossover.
Time frame: From start of treatment up to the earliest of progression, death or end of trial (up to 1 year).
Objective Response Based on Response Criteria for Intratumoural Immunotherapy in Solid Tumours (itRECIST)
Objective Response based on Response Criteria for Intratumoural Immunotherapy in Solid Tumours (itRECIST): (CTP version 3 and later) Objective response (OR) by itRECIST will be presented in terms of objective response rate (ORR), which is defined as the rate of patients whose best overall response is confirmed itCR or itPR as determined by the Investigator's assessment according to itRECIST from date of first treatment administration until the earliest of confirmed disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. Cross-over patients are shown in both Arm A (reflecting their initial treatment) and Arm B (reflecting their first treatment post-crossover). Their best overall response is counted, regardless of whether it occurred before or after the crossover.
Time frame: From start of treatment up to the earliest of progression, death or end of trial (approximately 1 year).
Best Percentage Change From Baseline in Size of Injected Lesions (CTP Version 1 or 2)
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of injected lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of injected lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP v1 and v2 using RECIST 1.1), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients appear in both Arm A (initial treatment) and Arm B (post-crossover treatment). Their best overall response is counted, regardless of timing. Negative values indicate a reduction in injected lesion diameters; positive values indicate an increase.
Time frame: From start of treatment up to the earliest of progression, death or end of trial (approximately 1 year).
Best Percentage Change From Baseline in Size of Injected Target Lesions (CTP v3.0 or Later Versions)
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of injected target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of injected target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP version 3 and later using itRECIST), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Negative values indicate reduced lesion diameters; positive values indicate increases. Cross-over patients are included in Arm A (initial treatment) and Arm B (first post-crossover treatment), with their best response counted regardless of timing.
Time frame: From start of treatment up to the earliest of progression, death or end of trial (approximately 1 year).
Best Percentage Change From Baseline in Size of Target Lesions (CTP Version 1 or 2)
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP v1 and v2 using RECIST 1.1), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients appear in both Arm A (initial treatment) and Arm B (post-crossover treatment). Their best overall response is counted, regardless of timing. Negative values indicate a reduction in lesion diameters; positive values indicate an increase.
Time frame: From start of treatment until the earliest of progression, death or end of trial (approximately 1 year).
Best Percentage Change From Baseline in Size of Non-injected Target Lesions (CTP v3.0 or Later Versions)
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of non-injected target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of non-injected target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP version 3 and later using itRECIST), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
Time frame: From start of treatment until the earliest of progression, death or end of trial (approximately 1 year).
This open-label, multicenter, 2-arm, dose-escalation trial evaluated BI 1387446 administered intratumorally into superficial lesions as a single agent (Arm A) or in combination with intravenous ezabenlimab (Arm B). The primary objectives were to assess safety, determine the maximum tolerated dose for both treatment approaches, and explore preliminary efficacy signals. Patients with progressive disease could cross over to Arm B after completing Cycle 1, provided Arm B is open for recruitment.
| Milestone | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 7 | 4 | 6 | 3 | 3 |
| Completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 8 | 6 | 4 | 6 | 3 | 3 |
| Withdrew: Clinical deterioration | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical disease progression | 1 | 3 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Objective disease progression | 6 | 4 | 3 | 3 | 5 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Objective response, as defined by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1), in accordance with Clinical Trial Protocol (CTP) Version 1 and 2, will be presented in terms of the objective response rate (ORR). The ORR is the proportion of patients whose best overall response is a confirmed complete response (CR) or partial response (PR). This determination is based on the investigator's assessment according to RECIST 1.1 criteria, from the date of the first treatment administration until the earliest occurrence of any of the following events: disease progression, death, the last evaluable tumor assessment before the initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients are shown in both Arm A (reflecting their initial treatment) and Arm B (reflecting their first treatment post-crossover). Their best overall response is counted, regardless of whether it occurred before or after the crossover.
| Participants | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Objective Response Based on Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | — | 0 (0 to 0) | 0 (0 to 0) | — |
Objective Response based on Response Criteria for Intratumoural Immunotherapy in Solid Tumours (itRECIST): (CTP version 3 and later) Objective response (OR) by itRECIST will be presented in terms of objective response rate (ORR), which is defined as the rate of patients whose best overall response is confirmed itCR or itPR as determined by the Investigator's assessment according to itRECIST from date of first treatment administration until the earliest of confirmed disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. Cross-over patients are shown in both Arm A (reflecting their initial treatment) and Arm B (reflecting their first treatment post-crossover). Their best overall response is counted, regardless of whether it occurred before or after the crossover.
| Participants | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Objective Response Based on Response Criteria for Intratumoural Immunotherapy in Solid Tumours (itRECIST) | — | — | 0 (0 to 0) | 1 (0.6 to 80.6) | — | 0 (0 to 0) | 1 (0.6 to 80.6) |
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of injected lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of injected lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP v1 and v2 using RECIST 1.1), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients appear in both Arm A (initial treatment) and Arm B (post-crossover treatment). Their best overall response is counted, regardless of timing. Negative values indicate a reduction in injected lesion diameters; positive values indicate an increase.
| Percent change | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Best Percentage Change From Baseline in Size of Injected Lesions (CTP Version 1 or 2) | 23.36 ± 28.94 | -20.73 ± 21.95 | -2.78 ± 3.93 | — | 0.54 ± 19.24 | 13.33 ± 18.86 | — |
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of injected target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of injected target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP version 3 and later using itRECIST), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Negative values indicate reduced lesion diameters; positive values indicate increases. Cross-over patients are included in Arm A (initial treatment) and Arm B (first post-crossover treatment), with their best response counted regardless of timing.
| Percent change | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Best Percentage Change From Baseline in Size of Injected Target Lesions (CTP v3.0 or Later Versions) | — | — | -6.67 ± 11.66 | -37.76 ± 52.67 | — | -17.43 ± 39.39 | -16.93 ± 58.42 |
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP v1 and v2 using RECIST 1.1), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. Cross-over patients appear in both Arm A (initial treatment) and Arm B (post-crossover treatment). Their best overall response is counted, regardless of timing. Negative values indicate a reduction in lesion diameters; positive values indicate an increase.
| Percent change | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Best Percentage Change From Baseline in Size of Target Lesions (CTP Version 1 or 2) | -0.07 ± 13.92 | 1.02 ± 6.89 | -0.10 ± 7.58 | — | 0.07 ± 13.98 | 0.25 ± 0.36 | — |
The MTD in each arm is defined as the highest dose that is expected to cause less than 25% risk of the true DLT rate being above or equal to 33% during the MTD evaluation period. Estimation of the MTD will be based upon the estimation of the posterior probability of the incidence of DLT in toxicity categories during the MTD evaluation period for all evaluable participants. The MTD evaluation period is defined as the time from the first administration of any trial medication to the start of the second treatment cycle. Specifically, this is the time from the first dose to either the second administration of ezabenlimab or the fourth administration of BI 1387446, whichever occurs first. If the second dose of ezabenlimab or the fourth dose of BI 1387446 is not given, the evaluation period ends 90 days after the last administration.
| μg (microgram) | Arm A: BI 1387446 | Arm B: BI 1387446 + Ezabenlimab |
|---|---|---|
| Maximum Tolerated Dose (MTD) Based on Number of Dose-limiting Toxicities (DLTs) | NA | NA |
The MTD evaluation period is defined as the time from the first administration of any trial medication to the start of the second treatment cycle. Specifically, this is the time from the first dose to either the second administration of ezabenlimab or the fourth administration of BI 1387446, whichever occurs first. If the second dose of ezabenlimab or the fourth dose of BI 1387446 is not given, the evaluation period ends 90 days after the last administration.
| Number of participants | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Number of Patients With DLT in the MTD Evaluation Period | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
This endpoint evaluated the best percentage change (i.e., greatest reduction) in the size of non-injected target lesions from baseline (the first measurement at the start of treatment) over time. The best percentage change from baseline in the size of non-injected target lesions was analyzed using descriptive statistics. All lesion measurements recorded from the start of trial treatment until the earliest of the following were considered: disease progression (assessed under CTP version 3 and later using itRECIST), initiation of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
| Percent change | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Best Percentage Change From Baseline in Size of Non-injected Target Lesions (CTP v3.0 or Later Versions) | — | — | -6.23 ± 6.23 | 1.30 ± 22.35 | — | 13.42 ± 14.14 | -17.28 ± 25.17 |
Collected over AE Collection Period: Arm A: From the first BI 1387446 dose until 90 days after the last dose (Residual Effect Period), or until the first Arm B dose, whichever occurred first - for a total duration of up to 14.8 months. Arm B: From the first trial drug dose until 90 days after the last dose (REP), for a total duration of up to 16.4 months. All-Cause Mortality: From the first trial drug dose plus 6 months follow-up after the last dose for a total duration of up to 19.4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 1387446 50 ug | 1/7 (14.3%) | 2/7 (28.6%) | 6/7 (85.7%) |
| BI 1387446 100 ug | 2/8 (25%) | 4/8 (50%) | 8/8 (100%) |
| BI 1387446 200 ug | 2/7 (28.6%) | 3/7 (42.9%) | 7/7 (100%) |
| BI 1387446 400 ug | 1/4 (25%) | 0/4 (0%) | 4/4 (100%) |
| BI 1387446 50 ug / Ezabenlimab 240 mg | 2/7 (28.6%) | 5/7 (71.4%) | 7/7 (100%) |
| BI 1387446 100 ug / Ezabenlimab 240 mg | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| BI 1387446 200 ug / Ezabenlimab 240 mg | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Event | BI 1387446 50 ug | BI 1387446 100 ug | BI 1387446 200 ug | BI 1387446 400 ug | BI 1387446 50 ug / Ezabenlimab 240 mg | BI 1387446 100 ug / Ezabenlimab 240 mg | BI 1387446 200 ug / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 2/8 | 2/7 | 0/4 | 3/7 | 1/5 | 0/4 |
| Splenic vein thrombosisBlood and lymphatic system disorders | 0/7 | 0/8 | 0/7 | 0/4 | 0/7 | 0/5 | 1/4 |
| PneumoniaInfections and infestations | 1/7 | 0/8 | 0/7 | 0/4 | 0/7 | 0/5 | 1/4 |
| SepsisInfections and infestations | 0/7 | 0/8 | 0/7 | 0/4 | 0/7 | 0/5 | 1/4 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/7 | 0/8 | 0/7 | 0/4 | 0/7 | 0/5 | 1/4 |
| Deep vein thrombosisVascular disorders | 0/7 | 0/8 | 0/7 | 0/4 | 0/7 | 0/5 | 1/4 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/7 | 0/8 | 0/7 | 0/4 | 0/7 | 1/5 | 0/4 |
| Liver disorderHepatobiliary disorders | 0/7 | 0/8 | 1/7 | 0/4 | 0/7 | 0/5 | 0/4 |
| InjuryInjury, poisoning and procedural complications | 0/7 | 0/8 | 0/7 | 0/4 | 1/7 | 0/5 | 0/4 |
| HypovolaemiaMetabolism and nutrition disorders | 0/7 | 0/8 | 0/7 | 0/4 | 1/7 | 0/5 | 0/4 |
| Event | BI 1387446 50 ug | BI 1387446 100 ug | BI 1387446 200 ug | BI 1387446 400 ug | BI 1387446 50 ug / Ezabenlimab 240 mg | BI 1387446 100 ug / Ezabenlimab 240 mg | BI 1387446 200 ug / Ezabenlimab 240 mg |
|---|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 1/7 | 1/8 | 0/7 | 0/4 | 2/7 | 2/5 | 3/4 |
| AnaemiaBlood and lymphatic system disorders | 0/7 | 3/8 | 1/7 | 1/4 | 2/7 | 2/5 | 2/4 |
| FatigueGeneral disorders | 2/7 | 4/8 | 1/7 | 0/4 | 2/7 | 1/5 | 0/4 |
| PyrexiaGeneral disorders | 0/7 | 2/8 | 2/7 | 0/4 | 0/7 | 0/5 | 2/4 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/8 | 0/7 | 1/4 | 1/7 | 0/5 | 2/4 |
| ConstipationGastrointestinal disorders | 0/7 | 2/8 | 2/7 | 1/4 | 1/7 | 2/5 | 1/4 |
| NauseaGastrointestinal disorders | 0/7 | 3/8 | 0/7 | 0/4 | 0/7 | 2/5 | 1/4 |
| Dry mouthGastrointestinal disorders | 0/7 | 0/8 | 0/7 | 1/4 | 2/7 | 0/5 | 0/4 |
| Injection site painGeneral disorders | 0/7 | 2/8 | 2/7 | 1/4 | 0/7 | 0/5 | 1/4 |
| Alanine aminotransferase increasedInvestigations | 0/7 | 1/8 | 2/7 | 1/4 | 0/7 | 0/5 | 1/4 |
Treated set (TS): This patient set includes all patients who were documented to have received at least one dose of any study medication. Cross-over patients are shown in both Arm A (reflecting their initial treatment) and Arm B (reflecting their first treatment post-crossover).
| Age, Customized(Years) | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Arm A | 62.0 ± 16.6 | 55.3 ± 10.1 | 65.0 ± 7.2 | 55.3 ± 24.4 | — | — | — | 59.7 ± 14.1 |
| Arm B | — | — | — | — | 48.6 ± 14.3 | 57.0 ± 18.6 | 47.3 ± 17.5 | 50.9 ± 16.0 |
| Sex/Gender, Customized(Participants) | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Arm A- male | 5 | 4 | 3 | 3 | — | — | — | 15 |
| Arm A- female | 2 | 4 | 4 | 1 | — | — | — | 11 |
| Arm B- male | — | — | — | — | 4 | 4 | 2 | 10 |
| Arm B- female | — | — | — | — | 3 | 1 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Arm A- Hispanic or Latino | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Arm A- Not Hispanic or Latino | 7 | 8 | 7 | 4 | — | — | — | 26 |
| Arm B- Hispanic or Latino | — | — | — | — | 1 | 0 | 0 | 1 |
| Arm B- Not Hispanic or Latino | — | — | — | — | 6 | 5 | 4 | 15 |
| Race/Ethnicity, Customized(Participants) | Arm A: BI 1387446 50 μg | Arm A: BI 1387446 100 μg | Arm A: BI 1387446 200 μg | Arm A: BI 1387446 400 μg | Arm B: BI 1387446 50 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 100 μg / Ezabenlimab 240 mg | Arm B: BI 1387446 200 μg / Ezabenlimab 240 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Arm A - Asian | 0 | 0 | 1 | 0 | — | — | — | 1 |
| Arm A- Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | — | — | — | 1 |
| Arm A - White | 6 | 8 | 6 | 4 | — | — | — | 24 |
| Arm B - Asian | — | — | — | — | 0 | 0 | 0 | 0 |
| Arm B- Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 | 0 | 0 |
| Arm B - White | — | — | — | — | 7 | 5 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Aug 2020 to primary completion in Nov 2022, 27 months.
Results were first posted in Jun 2025, 2 years 6 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 27 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezabenlimab